Ozone Therapy (Autohemotherapy / Insufflation) — Emerging and largely investigational

Independent of any benefit claim, the safety literature on ozone therapy lists fatigue and malaise among the common mild reactions to the sessions themselves, alongside rare but serious events such as stroke and pulmonary embolism tied to particular administration routes.

Both randomized trials that reported a short-term benefit from ozone autohemotherapy during COVID-19 delivered it under medical supervision as an adjunct alongside standard care in people who were acutely ill, not as a stand-alone or unsupervised wellness protocol. Their results describe short, monitored courses in one specific illness and should not be generalized to everyday immune-support use.

In knee osteoarthritis trials of ozone delivered by intra-articular joint injection, reported adverse events have been minor and infrequent, with no major complications recorded across controlled studies. Because no trial in this literature used autohemotherapy or insufflation, it does not establish the safety profile of those delivery routes.

A 2026 meta-analysis of 20 randomized trials in shingles-related nerve pain reported lower pain scores and lower IL-6 with ozone autohemotherapy versus comparators, while the pooled TNF-alpha estimate crossed the no-effect line and so was not statistically reliable. Heterogeneity was very high and GRADE certainty was very low for most outcomes, so this does not establish ozone as a reliable systemic anti-inflammatory option.

A small retrospective chart review of 25 people with fibromyalgia, a condition that overlaps with long-term fatigue, reported lower pain and lower questionnaire-impact scores after a 10-session ozone autohemotherapy course, with most of that change still present at six months and a small partial rebound in pain. Fatigue itself was described only as following a similar trend, with no published numbers and no six-month fatigue value.

In a 2022 pilot non-inferiority randomized trial (49 patients across three European centers), image-guided intradiscal oxygen-ozone injection produced 6-month leg-pain scores that met the trial's prespecified non-inferiority margin versus microdiscectomy surgery, and 71 percent (17 of 24) of the oxygen-ozone patients had not gone on to microdiscectomy by the 6-month mark, with a substantially shorter procedure and discharge time.

In a 60-patient phase I/II randomized trial, adding ozone therapy (rectal insufflation plus minor autohemotherapy) to standard care for mild-to-moderate COVID-19 was associated with faster time to a negative PCR result (p = 0.01) and with lower intensive-care requirement and better symptom scores (p < 0.05) versus standard care alone. No adverse events were reported in the 30-patient ozone arm. A single small early-phase trial is a preliminary signal, not a settled result.

In a randomized trial of adults with diabetic foot complications, rectal and topical ozone normalized oxidative-stress markers and activated the body's own antioxidant enzyme superoxide dismutase, alongside better wound outcomes and fewer amputations than the comparison group. This is an encouraging but disease-specific signal that is now two decades old.

In a small randomized, double-blind, placebo-controlled trial, adding paravertebral ozone injections to conservative care was associated with lower pain and disability scores than conservative care plus placebo injections in adults with acute lumbar disc herniation, with the largest gap at the final follow-up one month after the injection course ended.

In CORMOR, a 92-patient randomized trial run across four Italian centers, adding ozone autohemotherapy to standard care for COVID-19 pneumonia produced a better composite clinical-improvement score at day 7 (median 2 versus 0, p = 0.018), but showed no difference in mortality, intensive-care admission, or mechanical ventilation. The authors called for larger studies, so this reads as a modest short-term signal rather than a change in the course of the illness.

In a large single-arm case series with no comparison group, people with ME/CFS reported large drops in a standard fatigue-severity score 30 days after a course of oxygen-ozone autohemotherapy. Because nobody received a placebo or sham and nobody was blinded, the result cannot separate the sessions themselves from placebo response or natural symptom fluctuation.

For general wellness or 'detox' framing, there is no credible human evidence that ozone autohemotherapy or insufflation lowers everyday systemic inflammation; independent reviewers describe the evidence base as severely limited, and US federal device labeling rules state that ozone is a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy.

The most comprehensive synthesis of ozone therapy trials for knee osteoarthritis reports pain benefits but rates every underlying systematic review as critically low confidence, so those benefits should be regarded as unsettled rather than established, and effects on joint function were less consistent.